Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 1998

View Archived Issues

Fetal neural transplantation may be a potential treatment for Huntington's disease

JTP-2942 as a potential treatment for motor neuropathy

YM-377 as a treatment for coronary occlusive diseases

Cubist presents favorable efficacy data for daptomycin at ICAAC

Phase II primate study of 1F7 expanded; clinical testing in sight

Resten-NG on track for clinical testing

Bayer, Millennium form the largest drug discovery alliance in history

Novel AIDS therapeutic enters phase I/II testing in South Africa

Selective NHE-1 inhibitor from Merck KGaA produces significant cardioprotective effects

V-11294A: an orally active PDE4 inhibitor undergoes testing in healthy volunteers

Profile of new carbapenem antibiotic selected for activity against resistant pathogens

Zeneca's CysLT1 antagonist shows potential for once-daily dosing; efficacy studies warranted

In vivo efficacy and toxicity studies presented at ICAAC for T-3811ME

Clinical trial results for Ariflo presented at European congress

Data presented at ICAAC indicate efficacy of Sch-56592 in leishmaniasis and phaeohyphomycosis

LCB-2183 inhibits mast cell activation in vivo in mice

New 8-methoxyquinolone selected for development at Daiichi

Gliatech reports promising pilot clinical trial results with ADCON-P

Novel series of 1beta-methylcarbapenems under evaluation at Banyu

Nexell to acquire CellPro assets

Sibia Neurosciences completes single-dose trial with SIB-1553A and initiates multiple-dose study

Genelabs expands SKB's marketing rights for hepatitis E vaccine

First orally active, nonsteroidal antiprogestins reported by Ligand

Gene Logic completes acquisition of OncorMed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...